UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 114

Sortiert nach

Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy

Annals of oncology, 2019-01, Vol.30 (1), p.68-75

2019

Volltextzugriff (PDF)

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Annals of oncology, 2017-10, Vol.28 (10), p.2443

2017

Volltextzugriff (PDF)

Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial

Annals of oncology, 2021-01, Vol.32 (1), p.85-96

2021

Volltextzugriff (PDF)

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

Annals of oncology, 2018-06, Vol.29 (6), p.1402-1408

2018

Volltextzugriff (PDF)

A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma

Annals of oncology, 2015-01, Vol.26 (1), p.205-211

2015

Volltextzugriff (PDF)

Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis

Annals of oncology, 2017-09, Vol.28 (9), p.2135-2141

2017

Volltextzugriff (PDF)

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Annals of oncology, 2024-01, Vol.35 (1), p.77-90

2024

Volltextzugriff (PDF)

Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Annals of oncology, 2022-12, Vol.33 (12), p.1250

2022

Volltextzugriff (PDF)

Association between CYP2D6 10 genotype and survival of breast cancer patients receiving tamoxifen treatment

Annals of oncology, 2008-08, Vol.19 (8), p.1423-1429

2008

Volltextzugriff (PDF)

Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial

Annals of oncology, 2021-02, Vol.32 (2), p.218-228

2021

Volltextzugriff (PDF)

1991P Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial

Annals of oncology, 2023-10, Vol.34, p.S1062-S1062

2023

Volltextzugriff (PDF)

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study

Annals of oncology, 2024-02, Vol.35 (2), p.190-199

2024

Volltextzugriff (PDF)

30P Hes1 protein expression and its significance in resected small cell lung cancers

Annals of oncology, 2022-09, Vol.33, p.S555-S556

2022

Volltextzugriff (PDF)

The impact of N-ratio in minimizing stage migration phenomenon in gastric cancer patients with insufficient number or level of lymph node retrieved: results from a Chinese mono-institutional study in 2159 patients

Annals of oncology, 2009-05, Vol.20 (5), p.897-905

2009

Volltextzugriff (PDF)

Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer

Annals of oncology, 2018-08, Vol.29 (8), p.1741-1747

2018

Volltextzugriff (PDF)

A population-based cohort study in Taiwan––use of insulin sensitizers can decrease cancer risk in diabetic patients?

Annals of oncology, 2013-02, Vol.24 (2), p.523-530

2013

Volltextzugriff (PDF)

Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes

Annals of oncology, 2016-07, Vol.27 (7), p.1336-1341

2016

Volltextzugriff (PDF)

Efficacy and safety of apatinib for metastatic colorectal cancer in standard therapy failure

Annals of oncology, 2019-07, Vol.30, p.iv36-iv36

2019

Volltextzugriff (PDF)

2025P Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers

Annals of oncology, 2023-10, Vol.34, p.S1075-S1075

2023

Volltextzugriff (PDF)

A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer

Annals of oncology, 2011-09, Vol.22 (9), p.2057-2067

2011

Volltextzugriff (PDF)

Echinoside A, a new marine-derived anticancer saponin, targets topoisomerase2α by unique interference with its DNA binding and catalytic cycle

Annals of oncology, 2010-03, Vol.21 (3), p.597-607

2010

Volltextzugriff (PDF)

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07

Annals of oncology, 2013-03, Vol.24 (3), p.718-725

2013

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma

Annals of oncology, 2016-04, Vol.27 (4), p.680-687

2016

Volltextzugriff (PDF)

359MO Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma

Annals of oncology, 2023-11, Vol.34, p.S1609

2023

Volltextzugriff (PDF)

953P Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial

Annals of oncology, 2023-10, Vol.34, p.S597-S597

2023

Volltextzugriff (PDF)

1 – 25 von 114

Suche als RSS-Feed

Aktive Filter

KollektionElsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(114)
Mit Volltextzugriff
(114)

Publikationsform

Artikel
(114)

Sprache

Englisch
(114)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(23)
Life Sciences & Biomedicine
(22)
Oncology
(22)
Science & Technology
(22)
Female
(14)
Aged
(13)
Middle Aged
(13)
Male
(12)
Adult
(10)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Antineoplastic Agents
(9)
Pharmacology. Drug Treatments
(9)
Treatment Outcome
(9)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Disease-Free Survival
(7)
Mutation
(6)
Tumors
(6)
Follow-Up Studies
(5)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
(114)
Journals@Ovid Complete
(114)
MEDLINE
(23)
IngentaConnect
(20)
IngentaConnect Journals
(5)

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma

Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Association between CYP2D6 10 genotype and survival of breast cancer patients receiving tamoxifen treatment

Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial

1991P Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study

30P Hes1 protein expression and its significance in resected small cell lung cancers

The impact of N-ratio in minimizing stage migration phenomenon in gastric cancer patients with insufficient number or level of lymph node retrieved: results from a Chinese mono-institutional study in 2159 patients

Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer

A population-based cohort study in Taiwan––use of insulin sensitizers can decrease cancer risk in diabetic patients?

Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes

Efficacy and safety of apatinib for metastatic colorectal cancer in standard therapy failure

2025P Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers

A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer

Echinoside A, a new marine-derived anticancer saponin, targets topoisomerase2α by unique interference with its DNA binding and catalytic cycle

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma

359MO Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma

953P Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial

Aktive Filter

Suchergebnisse filtern